Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease

Neurobiology of Disease

Volumn 63, Issue , 2014, Pages 165-170

  Mutez, Eugénie ^a,b,c   Nkiliza, Aurore ^a,b   Belarbi, Karim ^a,b   de Broucker, Amélie ^a,b   Vanbesien Mailliot, Christel ^a,b   Bleuse, Séverine ^a,b,c   Duflot, Aurélie ^a,b   Comptdaer, Thomas ^a,b   Semaille, Pierre ^a,b   Blervaque, Renaud ^d   Hot, David ^d   Leprêtre, Frederic ^b   Figeac, Martin ^b   Destée, Alain ^a,b,c   Chartier Harlin, Marie Christine ^a,b  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSERM U1019   (France)

Author keywords

EIF2 signaling; Endocytosis; Immune response; LRRK2 mutation; Parkinson's disease; PBMC; Peripheral blood mononuclear cell; Transcriptome

Indexed keywords

INITIATION FACTOR 2; IRON; LEUCINE RICH REPEAT KINASE 2;

ADULT; ARTICLE; BLOOD SAMPLING; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; DOPAMINERGIC NERVE CELL; ENDOCYTOSIS; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; IRON METABOLISM; MALE; MIDDLE AGED; MITOCHONDRIAL RESPIRATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS;

EIF2 SIGNALING; ENDOCYTOSIS; IMMUNE RESPONSE; LRRK2 MUTATION; PARKINSON'S DISEASE; PBMC; PERIPHERAL BLOOD MONONUCLEAR CELL; TRANSCRIPTOME;

ADULT; AGED; AGED, 80 AND OVER; ENDOCYTOSIS; EUKARYOTIC INITIATION FACTOR-2; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNE SYSTEM; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84891113282     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.11.007     Document Type: Article

References (48)

1. Alvarez-Erviti L., Couch Y., Richardson J., Cooper J.M., Wood M.J. α-Synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci. Res. 2011, 69:337-342.
2. Angot E., Steiner J.A., Lema Tomé C.M., Ekström P., Mattsson B., Björklund A., et al. α-Synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 2012, 7:e39465.
3. Ben Gedalya T., Loeb V., Israeli E., Altschuler Y., Selkoe D.J., Sharon R. α-Synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 2009, 10:218-234.
4. Brochard V., Combadière B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192.
5. Camargos S., Scholz S., Simón-Sánchez J., Paisán-Ruiz C., Lewis P., Hernandez D., et al. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol. 2008, 7:207-215.
6. Chartier-Harlin M.C., Dachsel J.C., Vilariño-Güell C., Lincoln S.J., Leprêtre F., Hulihan M.M., et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am. J. Hum. Genet. 2011, 89:398-406.
7. Chen X., Wu G., Schwarzschild M.A. Urate in Parkinson's disease: more than a biomarker?. Curr. Neurol. Neurosci. Rep. 2012, 12:367-375.
8. Chinta S.J., Mallajosyula J.K., Rane A., Andersen J.K. Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 2010, 486:235-239.
9. Colombo C., Cosentino M., Marino F., Rasini E., Ossola M., Blandini F., et al. Dopaminergic modulation of apoptosis in human peripheral blood mononuclear cells: possible relevance for Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 1010:679-682.
10. Cooper-Knock J., Kirby J., Ferraiuolo L., Heath P.R., Rattray M., Shaw P.J. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol. 2012, 8:518-530.
11. Dehay B., Martinez-Vicente M., Caldwell G.A., Caldwell K.A., Yue Z., Cookson M.R., Klein C., et al. Lysosomal impairment in Parkinson's disease. Mov. Disord. 2013, 28:725-732.
12. Devine M.J., Plun-Favreau H., Wood N.W. Parkinson's disease and cancer: two wars, one front. Nat. Rev. Cancer 2011, 11:812-823.
13. Durrenberger P.F., Grünblatt E., Fernando F.S., Monoranu C.M., Evans J., Riederer P., et al. Inflammatory pathways in Parkinson's disease; a BNE microarray study. Parkinsons Dis. 2012, 2012:214714.
14. Elstner M., Morris C.M., Heim K., Bender A., Mehta D., Jaros E., et al. Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol. 2011, 122:75-86.
15. Ferree A., Guillily M., Li H., Smith K., Takashima A., Squillace R., et al. Regulation of physiologic actions of LRRK2: focus on autophagy. Neurodegener Dis 2012, 10:238-241.
16. Freeman D., Cedillos R., Choyke S., Lukic Z., McGuire K., et al. α-Synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013, 8:e62143.
17. Freundt E.C., Maynard N., Clancy E.K., Roy S., Bousset L., Sourigues Y., Covert M., Melki R., Kirkegaard K., Brahic M. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann. Neurol. 2012, 72:517-524.
18. Gardai S.J., Mao W., Schüle B., Babcock M., Schoebel S., Lorenzana C., et al. Elevated α-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One 2013, 8:e71634.
19. Gehrke S., Imai Y., Sokol N., Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010, 466:637-641.
20. Gibb W.R., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1988, 51:745-752.
21. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
22. Holmans P., Moskvina V., Jones L., Sharma M., International Parkinson's Disease Genomics Consortium, Vedernikov A., et al. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum. Mol. Genet. 2013, 22:1039-1049.
23. Hoozemans J.J., van Haastert E.S., Eikelenboom P., de Vos R.A., Rozemuller J.M., Scheper W. Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 2007, 354:707-711.
24. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106:518-526.
25. Jiang P., Gan M., Ebrahim A.S., Castanedes-Casey M., Dickson D.W., Yen S.H. Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of α-synuclein oligomers and decrease of neurites. Neurobiol. Aging 2013, 34:1504-1515.
26. Kohane I.S., Valtchinov V.I. Quantifying the white blood cell transcriptome as an accessible window to the multiorgan transcriptome. Bioinformatics 2012, 28:538-545.
27. Mandel S., Grunblatt E., Riederer P., Amariglio N., Jacob-Hirsch J., Rechavi G., et al. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann. N. Y. Acad. Sci. 2005, 1053:356-375.
28. Matta S., Van Kolen K., da Cunha R., van den Bogaart G., Mandemakers W., Miskiewicz K., et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.
29. Meixner A., Boldt K., Van Troys M., Askenazi M., Gloeckner C.J., Bauer M., et al. A QUICK screen for Lrrk2 interaction partners-leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol. Cell. Proteomics 2011, 10. (M110.001172).
30. Moreno J.A., Halliday M., Molloy C., Radford H., Verity N., Axten J.M., et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci. Transl. Med. 2013, 5:206ra138.
31. Mutez E., Larvor L., Leprêtre F., Mouroux V., Hamalek D., Kerckaert J.P., et al. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol. Aging 2011, 32:1839-1848.
32. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., et al. International Parkinson Disease Genomics Consortium, imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
33. Niwa F., Kuriyama N., Nakagawa M., Imanishi J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr. Gerontol. Int. 2012, 12:102-107.
34. Pan-Montojo F., Schwarz M., Winkler C., Arnhold M., O'Sullivan G.A., Pal A., et al. Environmental toxins trigger PD-like progression via increased α-synuclein release from enteric neurons in mice. Sci. Rep. 2012, 2:898.
35. Prigione A., Begni B., Galbussera A., Beretta S., Brighina L., Garofalo R., et al. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol. Dis. 2006, 23:36-43.
36. Ross O.A., Soto-Ortolaza A.I., Heckman M.G., Aasly J.O., Abahuni N., Annesi G., et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011, 10:898-908.
37. Scherzer C.R., Eklund A.C., Morse L.J., Liao Z., Locascio J.J., Fefer D., et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:955-960.
38. Scherzer C.R., Grass J.A., Liao Z., Pepivani I., Zheng B., Eklund A.C., et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10907-10912.
39. Shehadeh L.A., Yu K., Wang L., Guevara A., Singer C., Vance J., et al. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease. PLoS One 2010, 5:e9104.
40. Shinde S., Pasupathy K. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson's disease: preliminary study. Neurol. India 2006, 54:390-393. (Dec).
41. Simunovic F., Yi M., Wang Y., Macey L., Brown L.T., Krichevsky A.M., et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009, 132:1795-1809.
42. Singleton A.B., Farrer M.J., Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord. 2013, 28:14-23.
43. Tain L.S., Mortiboys H., Tao R.N., Ziviani E., Bandmann O., Whitworth A.J. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 2009, 12:1129-1135.
44. Taymans J.M. The GTPase function of LRRK2. Biochem. Soc. Trans. 2012, 40:1063-1069.
45. Thévenet J., Pescini Gobert R., Hooft van Huijsduijnen R., Wiessner C., Sagot Y.J. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One 2011, 6:e21519.
46. Ullrich C., Mlekusch R., Kuschnig A., Marksteiner J., Humpel C. Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients. Curr. Alzheimer Res. 2010, 7:549-555.
47. Yuan Y., Cao P., Smith M.A., Kramp K., Huang Y., Hisamoto N., et al. Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans. PLoS One 2011, 6:e22354.
48. Zheng B., Liao Z., Locascio J.J., Lesniak K.A., Roderick S.S., Watt M.L., et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2010, 2:52ra73.